{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:53:42Z","timestamp":1769021622216,"version":"3.49.0"},"reference-count":160,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/mkiv1986","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:34:00Z","timestamp":1713843240000},"page":"774-795","source":"Crossref","is-referenced-by-count":4,"title":["Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme"],"prefix":"10.62347","volume":"14","author":[{"given":"Willie","family":"Elliott Jr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.","journal-title":"N Engl J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-722.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bahr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schafer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C and Glas M; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393: 678-688.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, Stieber VW, Robins HI, Gray HJ, Voloschin A, Fiveash JB, Robinson CG, Chamarthy U, Kwok Y, Cescon TP, Sharma AK, Chaudhary R, Polley MY and Mehta MP. NRG\/RTOG 0837: randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv 2023; 5: vdad116.","DOI":"10.1093\/noajnl\/vdad116"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/ijms23010316","article-title":"Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma","volume":"23","author":"Videla-Richardson","year":"2021","unstructured":"Videla-Richardson GA, Morris-Hanon O, Torres NI, Esquivel MI, Vera MB, Ripari LB, Croci DO, Sevlever GE and Rabinovich GA. Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma. Int J Mol Sci 2021; 23: 316.","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Johannes L, Jacob R and Leffler H. Galectins at a glance. J Cell Sci 2018; 131: jcs208884.","DOI":"10.1242\/jcs.208884"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Kottgen E, Reutter W and Tauber R. Human lectins and their correspondent glycans in cell biology and clinical medicine. Med Klin (Munich) 2003; 98: 717-738.","DOI":"10.1007\/s00063-003-1318-1"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"119426","DOI":"10.1016\/j.lfs.2021.119426","article-title":"Targeting galectins in T cell-based immunotherapy within tumor microenvironment","volume":"277","author":"Jin","year":"2021","unstructured":"Jin QY, Li YS, Qiao XH, Yang JW and Guo XL. Targeting galectins in T cell-based immunotherapy within tumor microenvironment. Life Sci 2021; 277: 119426.","journal-title":"Life Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"14083","DOI":"10.3390\/ijms241814083","article-title":"Heterologous interactions with galectins and chemokines and their functional consequences","volume":"24","author":"Mayo","year":"2023","unstructured":"Mayo KH. Heterologous interactions with galectins and chemokines and their functional consequences. Int J Mol Sci 2023; 24: 14083.","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1145268","DOI":"10.3389\/fimmu.2023.1145268","article-title":"Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies","volume":"14","author":"Kapetanakis","year":"2023","unstructured":"Kapetanakis NI and Busson P. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies. Front Immunol 2023; 14: 1145268.","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbcan.2015.03.003","article-title":"Galectin expression in cancer diagnosis and prognosis: a systematic review","volume":"1855","author":"Thijssen","year":"2015","unstructured":"Thijssen VL, Heusschen R, Caers J and Griffioen AW. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta 2015; 1855: 235-247.","journal-title":"Biochim Biophys Acta"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1052959","DOI":"10.3389\/fcvm.2023.1052959","article-title":"Galectin functions in cancer-associated inflammation and thrombosis","volume":"10","author":"Kruk","year":"2023","unstructured":"Kruk L, Braun A, Cosset E, Gudermann T and Mammadova-Bach E. Galectin functions in cancer-associated inflammation and thrombosis. Front Cardiovasc Med 2023; 10: 1052959.","journal-title":"Front Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"20898","DOI":"10.1016\/S0021-9258(17)45301-4","article-title":"Primary structure of alanyl-tRNA synthetase and the regulation of its mRNA levels in Bombyx mori","volume":"265","author":"Chang","year":"1990","unstructured":"Chang PK and Dignam JD. Primary structure of alanyl-tRNA synthetase and the regulation of its mRNA levels in Bombyx mori. J Biol Chem 1990; 265: 20898-20906.","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14737175.2020.1750955","article-title":"The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases","volume":"20","author":"Ramirez Hernandez","year":"2020","unstructured":"Ramirez Hernandez E, Sanchez-Maldonado C, Mayoral Chavez MA, Hernandez-Zimbron LF, Patricio Martinez A, Zenteno E and Limon Perez de Leon ID. The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases. Expert Rev Neurother 2020; 20: 439-448.","journal-title":"Expert Rev Neurother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10719-022-10064-w","article-title":"Neuroinflammation and galectins: a key relationship in neurodegenerative diseases","volume":"39","author":"Ramirez Hernandez","year":"2022","unstructured":"Ramirez Hernandez E, Alanis Olvera B, Carmona Gonzalez D, Guerrero Marin O, Pantoja Mercado D, Valencia Gil L, Hernandez-Zimbron LF, Sanchez Salgado JL, Limon ID and Zenteno E. Neuroinflammation and galectins: a key relationship in neurodegenerative diseases. Glycoconj J 2022; 39: 685-699.","journal-title":"Glycoconj J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ijc.28426","article-title":"Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity","volume":"134","author":"Verschuere","year":"2014","unstructured":"Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW and De Vleeschouwer S. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 2014; 134: 873-884.","journal-title":"Int J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.nbd.2016.09.003","article-title":"Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization\/phagocytosis and oligodendroglial differentiation","volume":"96","author":"Rinaldi","year":"2016","unstructured":"Rinaldi M, Thomas L, Mathieu P, Carabias P, Troncoso MF, Pasquini JM, Rabinovich GA and Pasquini LA. Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization\/phagocytosis and oligodendroglial differentiation. Neurobiol Dis 2016; 96: 127-143.","journal-title":"Neurobiol Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1007\/s12035-022-03038-4","article-title":"Neuroprotective effect of exogenous galectin-1 in status epilepticus","volume":"59","author":"Pacheco","year":"2022","unstructured":"Pacheco ALD, de Melo IS, de Araujo Costa M, Amaral MMC, de Gusmao Taveiros Silva NK, Santos YMO, Gitai DLG, Duzzioni M, Borbely AU, Silva RS, Donatti ALF, Mestriner L, Fuzo CA, Cummings RD, Garcia-Cairasco N, Dias-Baruffi M and de Castro OW. Neuroprotective effect of exogenous galectin-1 in status epilepticus. Mol Neurobiol 2022; 59: 7354-7369.","journal-title":"Mol Neurobiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1158\/0008-5472.CAN-14-1203","article-title":"Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity","volume":"74","author":"Baker","year":"2014","unstructured":"Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG and Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res 2014; 74: 5079-5090.","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lowenstein PR, Baker GJ and Castro MG. Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy. Oncoimmunology 2014; 3: e965573.","DOI":"10.4161\/21624011.2014.965573"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/ijms21061954","article-title":"Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance","volume":"21","author":"Khan","year":"2020","unstructured":"Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V and de Groot JF. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. Int J Mol Sci 2020; 21: 1954.","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Baker GJ, Chockley P, Zamler D, Castro MG and Lowenstein PR. Natural killer cells require monocytic Gr-1(+)\/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology 2016; 5: e1163461.","DOI":"10.1080\/2162402X.2016.1163461"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41419-022-05024-z","article-title":"Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism","volume":"13","author":"Guda","year":"2022","unstructured":"Guda MR, Tsung AJ, Asuthkar S and Velpula KK. Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism. Cell Death Dis 2022; 13: 574.","journal-title":"Cell Death Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s12035-019-01787-3","article-title":"Galectin-3 exerts a pro-differentiating and pro-myelinating effect within a temporal window spanning precursors and pre-oligodendrocytes: insights into the mechanisms of action","volume":"57","author":"Thomas","year":"2020","unstructured":"Thomas L and Pasquini LA. Galectin-3 exerts a pro-differentiating and pro-myelinating effect within a temporal window spanning precursors and pre-oligodendrocytes: insights into the mechanisms of action. Mol Neurobiol 2020; 57: 976-987.","journal-title":"Mol Neurobiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/biom10050798","article-title":"Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior","volume":"10","author":"Srejovic","year":"2020","unstructured":"Srejovic I, Selakovic D, Jovicic N, Jakovljevic V, Lukic ML and Rosic G. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 2020; 10: 798.","journal-title":"Biomolecules"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y and Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 2018; 41: 599-614.","DOI":"10.3892\/ijmm.2017.3311"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.3892\/ol.2018.7931","article-title":"The role of galectin-3 in the tumorigenesis and progression of pituitary tumors","volume":"15","author":"Diao","year":"2018","unstructured":"Diao B, Liu Y, Xu GZ, Zhang Y, Xie J and Gong J. The role of galectin-3 in the tumorigenesis and progression of pituitary tumors. Oncol Lett 2018; 15: 4919-4925.","journal-title":"Oncol Lett"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, bak and beyond - mitochondrial performance in apoptosis","volume":"285","author":"Pena-Blanco","year":"2018","unstructured":"Pena-Blanco A and Garcia-Saez AJ. Bax, bak and beyond - mitochondrial performance in apoptosis. FEBS J 2018; 285: 416-431.","journal-title":"FEBS J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clinbiochem.2021.03.003","article-title":"Roles of matrix metalloproteinase-7 (MMP-7) in cancer","volume":"92","author":"Liao","year":"2021","unstructured":"Liao HY, Da CM, Liao B and Zhang HH. Roles of matrix metalloproteinase-7 (MMP-7) in cancer. Clin Biochem 2021; 92: 9-18.","journal-title":"Clin Biochem"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.3390\/cells10113047","article-title":"Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases","volume":"10","author":"LC","year":"2021","unstructured":"Soares LC, Al-Dalahmah O, Hillis J, Young CC, Asbed I, Sakaguchi M, O’Neill E and Szele FG. Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases. Cells 2021; 10: 3047.","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.celrep.2015.02.012","article-title":"Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation","volume":"10","author":"Burguillos","year":"2015","unstructured":"Burguillos MA, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, Santiago M, Viceconte N, Oliva-Martin MJ, Osman AM, Salomonsson E, Amar L, Persson A, Blomgren K, Achour A, Englund E, Leffler H, Venero JL, Joseph B and Deierborg T. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015; 10: 1626-1638.","journal-title":"Cell Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/ijms19082195","article-title":"Early hyperbaric oxygen treatment attenuates burn-induced neuroinflammation by inhibiting the galectin-3-dependent toll-like receptor-4 pathway in a rat model","volume":"19","author":"ZS","year":"2018","unstructured":"Wu ZS, Lo JJ, Wu SH, Wang CZ, Chen RF, Lee SS, Chai CY and Huang SH. Early hyperbaric oxygen treatment attenuates burn-induced neuroinflammation by inhibiting the galectin-3-dependent toll-like receptor-4 pathway in a rat model. Int J Mol Sci 2018; 19: 2195.","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0271678X20931137","article-title":"Galectin-3 protects against ischemic stroke by promoting neuro-angiogenesis via apoptosis inhibition and Akt\/Caspase regulation","volume":"41","author":"Wesley","year":"2021","unstructured":"Wesley UV, Sutton IC, Cunningham K, Jaeger JW, Phan AQ, Hatcher JF and Dempsey RJ. Galectin-3 protects against ischemic stroke by promoting neuro-angiogenesis via apoptosis inhibition and Akt\/Caspase regulation. J Cereb Blood Flow Metab 2021; 41: 857-873.","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","unstructured":"Shariati M and Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs 2019; 28: 977-988.","journal-title":"Expert Opin Investig Drugs"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"963689720906777","DOI":"10.1177\/0963689720906777","article-title":"Long noncoding RNA PCED1B-AS1 promotes the Warburg effect and tumorigenesis by upregulating HIF-1alpha in glioblastoma","volume":"29","author":"Yao","year":"2020","unstructured":"Yao Z, Zhang Q, Guo F, Guo S, Yang B, Liu B, Li P, Li J, Guan S and Liu X. Long noncoding RNA PCED1B-AS1 promotes the Warburg effect and tumorigenesis by upregulating HIF-1alpha in glioblastoma. Cell Transplant 2020; 29: 963689720906777.","journal-title":"Cell Transplant"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"20289","DOI":"10.1038\/srep20289","article-title":"Structural characterisation of human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol, lactose, 3’-sulfo-lactose, and 2’-fucosyllactose","volume":"6","author":"Bum-Erdene","year":"2016","unstructured":"Bum-Erdene K, Leffler H, Nilsson UJ and Blanchard H. Structural characterisation of human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol, lactose, 3’-sulfo-lactose, and 2’-fucosyllactose. Sci Rep 2016; 6: 20289.","journal-title":"Sci Rep"},{"key":"ref36","unstructured":"Acharjee A, Agarwal P, Nash K, Bano S, Rahman T and Gkoutos GV. Immune infiltration and prognostic and diagnostic use of LGALS4 in colon adenocarcinoma and bladder urothelial carcinoma. Am J Transl Res 2021; 13: 11353-11363."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/jnen\/nly081","article-title":"Galectin-4, a negative regulator of oligodendrocyte differentiation, is persistently present in axons and microglia\/macrophages in multiple sclerosis lesions","volume":"77","author":"Jong CGHM","year":"2018","unstructured":"de Jong CGHM, Stancic M, Pinxterhuis TH, van Horssen J, van Dam AM, Gabius HJ and Baron W. Galectin-4, a negative regulator of oligodendrocyte differentiation, is persistently present in axons and microglia\/macrophages in multiple sclerosis lesions. J Neuropathol Exp Neurol 2018; 77: 1024-1038.","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/bjc.2013.793","article-title":"Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis","volume":"110","author":"Chen","year":"2014","unstructured":"Chen C, Duckworth CA, Fu B, Pritchard DM, Rhodes JM and Yu LG. Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis. Br J Cancer 2014; 110: 741-752.","journal-title":"Br J Cancer"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Hong SH, Shin JS, Chung H and Park CG. Galectin-4 interaction with CD14 triggers the differentiation of monocytes into macrophage-like cells via the MAPK signaling pathway. Immune Netw 2019; 19: e17.","DOI":"10.4110\/in.2019.19.e17"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/cells11213485","article-title":"Normal cortical myelination in galectin-4-deficient mice","volume":"11","author":"Brocca","year":"2022","unstructured":"Brocca ME, Mora-Rubio A, Alonso-Calvino E, Fernandez-Lopez E, Diez-Revuelta N, Martos-Punal D, Aguilar J, Higuero AM and Abad-Rodriguez J. Normal cortical myelination in galectin-4-deficient mice. Cells 2022; 11: 3485.","journal-title":"Cells"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"12246","DOI":"10.1038\/s41598-017-12295-6","article-title":"Neurons define non-myelinated axon segments by the regulation of galectin-4-containing axon membrane domains","volume":"7","author":"Diez-Revuelta","year":"2017","unstructured":"Diez-Revuelta N, Higuero AM, Velasco S, Penas-de-la-Iglesia M, Gabius HJ and Abad-Rodriguez J. Neurons define non-myelinated axon segments by the regulation of galectin-4-containing axon membrane domains. Sci Rep 2017; 7: 12246.","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.molimm.2015.09.012","article-title":") and its response to bacterial infection","volume":"68","author":"Unajak","year":"2015","unstructured":"Unajak S, Pholmanee N, Songtawee N, Srikulnath K, Srisapoome P, Kiataramkul A, Kondo H, Hirono I and Areechon N. Molecular characterization of Galectin-8 from Nile tilapia (Oreochromis niloticus Linn.) and its response to bacterial infection. Mol Immunol 2015; 68: 585-596.","journal-title":"Mol Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/glycob\/cwu060","article-title":"Galectin-8 elicits pro-inflammatory activities in the endothelium","volume":"24","author":"Cattaneo","year":"2014","unstructured":"Cattaneo V, Tribulatti MV, Carabelli J, Carestia A, Schattner M and Campetella O. Galectin-8 elicits pro-inflammatory activities in the endothelium. Glycobiology 2014; 24: 966-973.","journal-title":"Glycobiology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1042\/BST20200677","article-title":"Galectin-8, cytokines, and the storm","volume":"50","author":"Zick","year":"2022","unstructured":"Zick Y. Galectin-8, cytokines, and the storm. Biochem Soc Trans 2022; 50: 135-149.","journal-title":"Biochem Soc Trans"},{"key":"ref45","unstructured":"Elola MT, Ferragut F, Cardenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Troncoso MF, Compagno D, Wolfenstein-Todel C and Rabinovich GA. Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol Histopathol 2014; 29: 1093-1105."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1189\/jlb.3A0816-357RR","article-title":"Galectin-8 activates dendritic cells and stimulates antigen-specific immune response elicitation","volume":"102","author":"Carabelli","year":"2017","unstructured":"Carabelli J, Quattrocchi V, D’Antuono A, Zamorano P, Tribulatti MV and Campetella O. Galectin-8 activates dendritic cells and stimulates antigen-specific immune response elicitation. J Leukoc Biol 2017; 102: 1237-1247.","journal-title":"J Leukoc Biol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/glycob\/cwu054","article-title":"Galectin-8: a matricellular lectin with key roles in angiogenesis","volume":"24","author":"Troncoso","year":"2014","unstructured":"Troncoso MF, Ferragut F, Bacigalupo ML, Cardenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Wolfenstein-Todel C, Compagno D, Rabinovich GA and Elola MT. Galectin-8: a matricellular lectin with key roles in angiogenesis. Glycobiology 2014; 24: 907-914.","journal-title":"Glycobiology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.21873\/anticanres.14300","article-title":"Galectin-8 favors VEGF-induced angiogenesis: in vitro study in human umbilical vein endothelial cells and in vivo study in chick chorioallantoic membrane","volume":"40","author":"Varinska","year":"2020","unstructured":"Varinska L, Faber L, Petrovova E, Balazova L, Ivancova E, Kolar M and Gal P. Galectin-8 favors VEGF-induced angiogenesis: in vitro study in human umbilical vein endothelial cells and in vivo study in chick chorioallantoic membrane. Anticancer Res 2020; 40: 3191-3201.","journal-title":"Anticancer Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","article-title":"Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium","volume":"17","author":"Barrow","year":"2011","unstructured":"Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM and Yu LG. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 2011; 17: 7035-7046.","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbamcr.2019.03.010","article-title":"Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM\/CD166), synergistically delays in vivo breast cancer growth","volume":"1866","author":"Ferragut","year":"2019","unstructured":"Ferragut F, Cagnoni AJ, Colombo LL, Sanchez Terrero C, Wolfenstein-Todel C, Troncoso MF, Vanzulli SI, Rabinovich GA, Marino KV and Elola MT. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM\/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta Mol Cell Res 2019; 1866: 1338-1352.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/ars.2013.5371","article-title":"An overview of autophagy: morphology, mechanism, and regulation","volume":"20","author":"Parzych","year":"2014","unstructured":"Parzych KR and Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal 2014; 20: 460-473.","journal-title":"Antioxid Redox Signal"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-023-00466-9","article-title":"Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy","volume":"11","author":"Liu","year":"2023","unstructured":"Liu D, Zhu H and Li C. Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy. Biomark Res 2023; 11: 22.","journal-title":"Biomark Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1074\/jbc.M117.809293","article-title":"Galectin-8-mediated selective autophagy protects against seeded tau aggregation","volume":"293","author":"Falcon","year":"2018","unstructured":"Falcon B, Noad J, McMahon H, Randow F and Goedert M. Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J Biol Chem 2018; 293: 2438-2451.","journal-title":"J Biol Chem"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1080\/15548627.2019.1628548","article-title":"CALCOCO2\/NDP52 initiates selective autophagy through recruitment of ULK and TBK1 kinase complexes","volume":"15","author":"KB","year":"2019","unstructured":"Boyle KB, Ravenhill BJ and Randow F. CALCOCO2\/NDP52 initiates selective autophagy through recruitment of ULK and TBK1 kinase complexes. Autophagy 2019; 15: 1655-1656.","journal-title":"Autophagy"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"20526","DOI":"10.1038\/s41598-021-00170-4","article-title":"ULK1 promotes mitophagy via phosphorylation and stabilization of BNIP3","volume":"11","author":"Poole","year":"2021","unstructured":"Poole LP, Bock-Hughes A, Berardi DE and Macleod KF. ULK1 promotes mitophagy via phosphorylation and stabilization of BNIP3. Sci Rep 2021; 11: 20526.","journal-title":"Sci Rep"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Herhaus L. TBK1 (TANK-binding kinase 1)-mediated regulation of autophagy in health and disease. Matrix Biol 2021; 100-101: 84-98.","DOI":"10.1016\/j.matbio.2021.01.004"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-016-0091-6","article-title":"Galectin-8 promotes migration and proliferation and prevents apoptosis in U87 glioblastoma cells","volume":"49","author":"Metz","year":"2016","unstructured":"Metz C, Doger R, Riquelme E, Cortes P, Holmes C, Shaughnessy R, Oyanadel C, Grabowski C, Gonzalez A and Soza A. Galectin-8 promotes migration and proliferation and prevents apoptosis in U87 glioblastoma cells. Biol Res 2016; 49: 33.","journal-title":"Biol Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"104287","DOI":"10.1016\/j.cellimm.2021.104287","article-title":"Galectin-9 as a biomarker of disease severity","volume":"361","author":"Moar","year":"2021","unstructured":"Moar P and Tandon R. Galectin-9 as a biomarker of disease severity. Cell Immunol 2021; 361: 104287.","journal-title":"Cell Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2022","unstructured":"Lv Y, Ma X, Ma Y, Du Y and Feng J. A new emerging target in cancer immunotherapy: galectin-9 (LGALS9). Genes Dis 2022; 10: 2366-2382.","journal-title":"Genes Dis"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","unstructured":"Das M, Zhu C and Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 2017; 276: 97-111.","journal-title":"Immunol Rev"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Ni X, Wu W, Sun X, Ma J, Yu Z, He X, Cheng J, Xu P, Liu H, Shang T, Xi S, Wang J, Zhang J and Chen Z. Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv 2022; 8: eabl5165.","DOI":"10.1126\/sciadv.abl5165"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrodan L, Garcia-Moure M, Gonzalez-Huarriz M, Hervas-Corpion I, Dhandapani L, Vicent S, Collantes M, Penuelas I, Becher OJ, Filbin MG, Jiang L, Labelle J, de Biagi-Junior CAO, Nazarian J, Laternser S, Phoenix TN, van der Lugt J, Kranendonk M, Hoogendijk R, Mueller S, De Andrea C, Anderson AC, Guruceaga E, Koschmann C, Yadav VN, Gallego Perez-Larraya J, Patino-Garcia A, Pastor F and Alonso MM. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell 2023; 41: 1911-1926, e8.","DOI":"10.1016\/j.ccell.2023.09.001"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/cns.13100","article-title":"Negative regulation of glial Tim-3 inhibits the secretion of inflammatory factors and modulates microglia to antiinflammatory phenotype after experimental intracerebral hemorrhage in rats","volume":"25","author":"Chen","year":"2019","unstructured":"Chen ZQ, Yu H, Li HY, Shen HT, Li X, Zhang JY, Zhang ZW, Wang Z and Chen G. Negative regulation of glial Tim-3 inhibits the secretion of inflammatory factors and modulates microglia to antiinflammatory phenotype after experimental intracerebral hemorrhage in rats. CNS Neurosci Ther 2019; 25: 674-684.","journal-title":"CNS Neurosci Ther"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/biom11101398","article-title":"Immunosuppressive roles of galectin-1 in the tumor microenvironment","volume":"11","author":"Huang","year":"2021","unstructured":"Huang Y, Wang HC, Zhao J, Wu MH and Shih TC. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules 2021; 11: 1398.","journal-title":"Biomolecules"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3171\/JNS\/2008\/109\/8\/0273","article-title":"Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines","volume":"109","author":"Jung","year":"2008","unstructured":"Jung TY, Jung S, Ryu HH, Jeong YI, Jin YH, Jin SG, Kim IY, Kang SS and Kim HS. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 2008; 109: 273-284.","journal-title":"J Neurosurg"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/NEN.0b013e318170f892","article-title":"Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses","volume":"67","author":"Le Mercier","year":"2008","unstructured":"Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R and Lefranc F. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 2008; 67: 456-469.","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ijc.32102","article-title":"Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma","volume":"145","author":"Chen","year":"2019","unstructured":"Chen Q, Han B, Meng X, Duan C, Yang C, Wu Z, Magafurov D, Zhao S, Safin S, Jiang C and Cai J. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma. Int J Cancer 2019; 145: 517-530.","journal-title":"Int J Cancer"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1750-3639.2008.00227.x","article-title":"Galectin-1 is implicated in the protein kinase C epsilon\/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells","volume":"20","author":"Fortin","year":"2010","unstructured":"Fortin S, Le Mercier M, Camby I, Spiegl-Kreinecker S, Berger W, Lefranc F and Kiss R. Galectin-1 is implicated in the protein kinase C epsilon\/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol 2010; 20: 39-49.","journal-title":"Brain Pathol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1892265","DOI":"10.1080\/2162402X.2021.1892265","article-title":"Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity","volume":"10","author":"Sturgill","year":"2021","unstructured":"Sturgill ER, Rolig AS, Linch SN, Mick C, Kasiewicz MJ, Sun Z, Traber PG, Shlevin H and Redmond WL. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology 2021; 10: 1892265.","journal-title":"Oncoimmunology"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3892\/mmr.2017.6646","article-title":"Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice","volume":"16","author":"Lu","year":"2017","unstructured":"Lu Y, Zhang M, Zhao P, Jia M, Liu B, Jia Q, Guo J, Dou L and Li J. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep 2017; 16: 647-653.","journal-title":"Mol Med Rep"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1021\/acs.jmedchem.6b00957","article-title":"A selective galactose-coumarin-derived galectin-3 inhibitor demonstrates involvement of galectin-3-glycan interactions in a pulmonary fibrosis model","volume":"59","author":"Rajput","year":"2016","unstructured":"Rajput VK, MacKinnon A, Mandal S, Collins P, Blanchard H, Leffler H, Sethi T, Schambye H, Mukhopadhyay B and Nilsson UJ. A selective galactose-coumarin-derived galectin-3 inhibitor demonstrates involvement of galectin-3-glycan interactions in a pulmonary fibrosis model. J Med Chem 2016; 59: 8141-8147.","journal-title":"J Med Chem"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Caniglia JL, Guda MR, Asuthkar S, Tsung AJ and Velpula KK. A potential role for Galectin-3 inhibitors in the treatment of COVID-19. PeerJ 2020; 8: e9392.","DOI":"10.7717\/peerj.9392"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Attar A","year":"2021","unstructured":"Al Attar A, Antaramian A and Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol 2021; 14: 457-464.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jaad.2017.05.055","article-title":"A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis","volume":"77","author":"Ritchie","year":"2017","unstructured":"Ritchie S, Neal D, Shlevin H, Allgood A and Traber P. A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2017; 77: 753-755.","journal-title":"J Am Acad Dermatol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","article-title":"Development of siRNA-loaded chitosan nanoparticles targeting galectin-1 for the treatment of glioblastoma multiforme via intranasal administration","volume":"227","author":"Van Woensel","year":"2016","unstructured":"Van Woensel M, Wauthoz N, Rosiere R, Mathieu V, Kiss R, Lefranc F, Steelant B, Dilissen E, Van Gool SW, Mathivet T, Gerhardt H, Amighi K and De Vleeschouwer S. Development of siRNA-loaded chitosan nanoparticles targeting galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release 2016; 227: 71-81.","journal-title":"J Control Release"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijpharm.2015.01.051","article-title":"Combined anti-galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation","volume":"481","author":"Danhier","year":"2015","unstructured":"Danhier F, Messaoudi K, Lemaire L, Benoit JP and Lagarce F. Combined anti-galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. Int J Pharm 2015; 481: 154-161.","journal-title":"Int J Pharm"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.3390\/ijms21239232","article-title":"Galectin-3 in cardiovascular diseases","volume":"21","author":"Blanda","year":"2020","unstructured":"Blanda V, Bracale UM, Di Taranto MD and Fortunato G. Galectin-3 in cardiovascular diseases. Int J Mol Sci 2020; 21: 9232.","journal-title":"Int J Mol Sci"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","unstructured":"Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sadaba JR, Zannad F, Rossignol P and Lopez-Andres N. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015; 3: 59-67.","journal-title":"JACC Heart Fail"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1021\/acs.jmedchem.1c01296","article-title":"Novel selective galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia","volume":"65","author":"Bum-Erdene","year":"2022","unstructured":"Bum-Erdene K, Collins PM, Hugo MW, Tarighat SS, Fei F, Kishor C, Leffler H, Nilsson UJ, Groffen J, Grice ID, Heisterkamp N and Blanchard H. Novel selective galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia. J Med Chem 2022; 65: 5975-5989.","journal-title":"J Med Chem"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","unstructured":"Sumida Y and Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol 2018; 53: 362-376.","journal-title":"J Gastroenterol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/jnci\/94.24.1854","article-title":"Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin","volume":"94","author":"Nangia-Makker","year":"2002","unstructured":"Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R and Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854-1862.","journal-title":"J Natl Cancer Inst"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/jnci\/87.5.348","article-title":"Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin","volume":"87","author":"Pienta","year":"1995","unstructured":"Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V and Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348-353.","journal-title":"J Natl Cancer Inst"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/onc.2016.306","article-title":"RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways","volume":"36","author":"Zhang","year":"2017","unstructured":"Zhang L, Wang P, Qin Y, Cong Q, Shao C, Du Z, Ni X, Li P and Ding K. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene 2017; 36: 1297-1308.","journal-title":"Oncogene"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E and Chiriva-Internati M. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol 2014; 33: 417-427.","DOI":"10.3109\/08830185.2014.911855"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1164\/rccm.202203-0477OC","article-title":"An inhaled galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib\/IIa randomized controlled clinical trial (DEFINE)","volume":"207","author":"EE","year":"2023","unstructured":"Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O’Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T and Dhaliwal K. An inhaled galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib\/IIa randomized controlled clinical trial (DEFINE). Am J Respir Crit Care Med 2023; 207: 138-149.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/glycob\/cwy001","article-title":"Galectin-3 and cancer stemness","volume":"28","author":"Nangia-Makker P","year":"2018","unstructured":"Nangia-Makker P, Hogan V and Raz A. Galectin-3 and cancer stemness. Glycobiology 2018; 28: 172-181.","journal-title":"Glycobiology"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.3390\/nu13124295","article-title":"Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: results of a prospective phase II study","volume":"13","author":"Keizman","year":"2021","unstructured":"Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Margel D, Wolf I, Geva R, Dresler H, Rouvinov K, Rapoport N and Eliaz I. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: results of a prospective phase II study. Nutrients 2021; 13: 4295.","journal-title":"Nutrients"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-023-04513-y","article-title":"Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants","volume":"91","author":"Aslanis","year":"2023","unstructured":"Aslanis V, Slack RJ, MacKinnon AC, McClinton C, Tantawi S, Gravelle L, Nilsson UJ, Leffler H, Brooks A, Khindri SK, Marshall RP, Pedersen A, Schambye H and Zetterberg F. Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer Chemother Pharmacol 2023; 91: 267-280.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death","volume":"115","author":"Streetly","year":"2010","unstructured":"Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG and Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010; 115: 3939-3948.","journal-title":"Blood"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12885-018-4025-2","article-title":"Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy","volume":"18","author":"Chou","year":"2018","unstructured":"Chou SY, Yen SL, Huang CC and Huang EY. Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. BMC Cancer 2018; 18: 105.","journal-title":"BMC Cancer"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.bbrc.2004.10.181","article-title":"Multifaceted role of galectin-3 on human glioblastoma cell motility","volume":"325","author":"Debray","year":"2004","unstructured":"Debray C, Vereecken P, Belot N, Teillard P, Brion JP, Pandolfo M and Pochet R. Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 2004; 325: 1393-1398.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1208\/s12249-021-01928-9","article-title":"Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems","volume":"22","author":"Wiwatchaitawee","year":"2021","unstructured":"Wiwatchaitawee K, Quarterman JC, Geary SM and Salem AK. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech 2021; 22: 71.","journal-title":"AAPS PharmSciTech"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejpb.2021.08.011","article-title":"Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers","volume":"168","author":"Delello Di Filippo","year":"2021","unstructured":"Delello Di Filippo L, Hofstatter Azambuja J, Paes Dutra JA, Tavares Luiz M, Lobato Duarte J, Nicoleti LR, Olalla Saad ST and Chorilli M. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Eur J Pharm Biopharm 2021; 168: 76-89.","journal-title":"Eur J Pharm Biopharm"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Wu T, Liu Y, Cao Y and Liu Z. Engineering macrophage exosome disguised biodegradable nanoplatform for enhanced sonodynamic therapy of glioblastoma. Adv Mater 2022; 34: e2110364.","DOI":"10.1002\/adma.202110364"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S, Pan Z, Zhao S, Guo Q, Qi Y, Wang W, Deng L, Ni S, Sang Y, Xue H, Liu H and Li G. Synchronous disintegration of ferroptosis defense axis via engineered exosome-conjugated magnetic nanoparticles for glioblastoma therapy. Adv Sci (Weinh) 2022; 9: e2105451.","DOI":"10.1002\/advs.202105451"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Zou Y, Wang Y, Xu S, Liu Y, Yin J, Lovejoy DB, Zheng M, Liang XJ, Park JB, Efremov YM, Ulasov I and Shi B. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater 2022; 34: e2203958.","DOI":"10.1002\/adma.202203958"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"5284728","DOI":"10.1155\/2020\/5284728","article-title":"Galectin-3 is a potential mediator for atherosclerosis","volume":"2020","author":"Gao","year":"2020","unstructured":"Gao Z, Liu Z, Wang R, Zheng Y, Li H and Yang L. Galectin-3 is a potential mediator for atherosclerosis. J Immunol Res 2020; 2020: 5284728.","journal-title":"J Immunol Res"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","unstructured":"Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM and Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28: 433-440.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update","volume":"8","author":"Suthahar","year":"2018","unstructured":"Suthahar N, Meijers WC, Sillje HHW, Ho JE, Liu FT and de Boer RA. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics 2018; 8: 593-609.","journal-title":"Theranostics"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jacc.2020.07.044","article-title":"Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure","volume":"76","author":"Suthahar","year":"2020","unstructured":"Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, Benjamin EJ, Allison MA, Bartz TM, Januzzi JL Jr, Levy D, Meems LMG, Bakker SJL, Lima JAC, Cushman M, Lee DS, Wang TJ, deFilippi CR, Herrington DM, Nayor M, Vasan RS, Gardin JM, Kizer JR, Bertoni AG, Allen NB, Gansevoort RT, Shah SJ, Gottdiener JS, Ho JE and de Boer RA. Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure. J Am Coll Cardiol 2020; 76: 1455-1465.","journal-title":"J Am Coll Cardiol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"MR","year":"2019","unstructured":"Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M and Rouleau J. Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol 2019; 73: 795-806.","journal-title":"J Am Coll Cardiol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cardfail.2013.11.011","article-title":"Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION","volume":"20","author":"Fiuzat","year":"2014","unstructured":"Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Pina IL, Whellan DJ and O’Connor CM. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail 2014; 20: 38-44.","journal-title":"J Card Fail"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1253\/circj.CJ-17-0656","article-title":"Galectin-3 and the mineralocorticoid receptor antagonist canrenone in mild heart failure","volume":"81","author":"Clemenza","year":"2017","unstructured":"Clemenza F, Masson S, Conaldi PG, Di Carlo D, Boccanelli A, Mureddu GF, Gonzini L, Lucci D, Maggioni AP, Di Lenarda A, Nicolis EB, Vanasia M and Latini R; AREA IN-CHF Investigators. Galectin-3 and the mineralocorticoid receptor antagonist canrenone in mild heart failure. Circ J 2017; 81: 1543-1546.","journal-title":"Circ J"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","article-title":"Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice","volume":"67","author":"Vergaro","year":"2016","unstructured":"Vergaro G, Prud’homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A and Delcayre C. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension 2016; 67: 606-612.","journal-title":"Hypertension"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Luo H, Liu B, Zhao L, He J, Li T, Zha L, Li X, Qi Q, Liu Y and Yu Z. Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension. J Am Soc Hypertens 2017; 11: 673-683, e3.","DOI":"10.1016\/j.jash.2017.07.009"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"2002559","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","unstructured":"Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA and Maher TM. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J 2021; 57: 2002559.","journal-title":"Eur Respir J"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3389\/fimmu.2020.02069","article-title":"Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider","volume":"11","author":"Garcia-Revilla","year":"2020","unstructured":"Garcia-Revilla J, Deierborg T, Venero JL and Boza-Serrano A. Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider. Front Immunol 2020; 11: 2069.","journal-title":"Front Immunol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/vaccines11040731","article-title":"An oral galectin inhibitor in COVID-19-a phase II randomized controlled trial","volume":"11","author":"Sigamani","year":"2023","unstructured":"Sigamani A, Mayo KH, Miller MC, Chen-Walden H, Reddy S and Platt D. An oral galectin inhibitor in COVID-19-a phase II randomized controlled trial. Vaccines (Basel) 2023; 11: 731.","journal-title":"Vaccines (Basel)"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Traber PG and Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 2013; 8: e83481.","DOI":"10.1371\/journal.pone.0083481"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","unstructured":"Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, Noureddin M, Schiano TD, Siddiqui M, Sanyal A, Neuschwander-Tetri BA and Traber PG. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther 2016; 44: 1183-1198.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA and Traber PG; Belapectin (GR-MD-02) Study Investigators. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 2020; 158: 1334-1345, e5.","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","article-title":"Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy","volume":"7","author":"Dama","year":"2019","unstructured":"Dama P, Tang M, Fulton N, Kline J and Liu H. Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer 2019; 7: 175.","journal-title":"J Immunother Cancer"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2018.11.019","article-title":"Galectins as potential emerging key targets in different types of leukemia","volume":"844","author":"Zheng","year":"2019","unstructured":"Zheng Y, Feng W, Wang YJ, Sun Y, Shi G and Yu Q. Galectins as potential emerging key targets in different types of leukemia. Eur J Pharmacol 2019; 844: 73-78.","journal-title":"Eur J Pharmacol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbamcr.2015.12.008","article-title":"Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells","volume":"1863","author":"Ruvolo","year":"2016","unstructured":"Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N Jr, Davis RE and Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 2016; 1863: 562-571.","journal-title":"Biochim Biophys Acta"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-018-0721-7","article-title":"Treatment of B-cell precursor acute lymphoblastic leukemia with the galectin-1 inhibitor PTX008","volume":"37","author":"Paz","year":"2018","unstructured":"Paz H, Joo EJ, Chou CH, Fei F, Mayo KH, Abdel-Azim H, Ghazarian H, Groffen J and Heisterkamp N. Treatment of B-cell precursor acute lymphoblastic leukemia with the galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 2018; 37: 67.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Wang Y, Nangia-Makker P, Balan V, Hogan V and Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 2010; 1: e101.","DOI":"10.1038\/cddis.2010.79"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s13046-019-1402-x","article-title":"Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells","volume":"38","author":"Leung","year":"2019","unstructured":"Leung Z, Ko FCF, Tey SK, Kwong EML, Mao X, Liu BHM, Ma APY, Fung YME, Che CM, Wong DKH, Lai CL, Ng IO and Yam JWP. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. J Exp Clin Cancer Res 2019; 38: 423.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.livres.2020.11.001","article-title":"Overexpression of galectin-1 and galectin-3 in hepatocellular carcinoma","volume":"4","author":"Setayesh","year":"2020","unstructured":"Setayesh T, Colquhoun SD and Wan YY. Overexpression of galectin-1 and galectin-3 in hepatocellular carcinoma. Liver Res 2020; 4: 173-179.","journal-title":"Liver Res"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/ijms18122671","article-title":"Galectin-1 inhibitor OTX008 induces tumor vessel normalization and tumor growth inhibition in human head and neck squamous cell carcinoma models","volume":"18","author":"NA","year":"2017","unstructured":"Koonce NA, Griffin RJ and Dings RPM. Galectin-1 inhibitor OTX008 induces tumor vessel normalization and tumor growth inhibition in human head and neck squamous cell carcinoma models. Int J Mol Sci 2017; 18: 2671.","journal-title":"Int J Mol Sci"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, Bartolazzi A, Gulino A and Giannini G. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One 2012; 7: e49139.","DOI":"10.1371\/journal.pone.0049139"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-18-2244","article-title":"An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade","volume":"79","author":"Vuong","year":"2019","unstructured":"Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T and MacKinnon AC. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res 2019; 79: 1480-1492.","journal-title":"Cancer Res"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton JR, Shlevin H and Redmond WL. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J Immunother Cancer 2021; 9: e002371.","DOI":"10.1136\/jitc-2021-002371"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2014.09.021","article-title":"Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer","volume":"135","author":"Mirandola","year":"2014","unstructured":"Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA and Chiriva-Internati M. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol 2014; 135: 573-579.","journal-title":"Gynecol Oncol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy","volume":"11","author":"Gregory","year":"2020","unstructured":"Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, Lowenstein PR, Castro MG and Lahann J. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun 2020; 11: 5687.","journal-title":"Nat Commun"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Zou Y, Sun X, Wang Y, Yan C, Liu Y, Li J, Zhang D, Zheng M, Chung RS and Shi B. Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Adv Mater 2020; 32: e2000416.","DOI":"10.1002\/adma.202000416"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Messaoudi K, Saulnier P, Boesen K, Benoit JP and Lagarce F. Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedicine 2014; 9: 1479-1490.","DOI":"10.2147\/IJN.S59134"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-023-04257-y","article-title":"T7 peptide-decorated exosome-based nanocarrier system for delivery of galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma","volume":"162","author":"Li","year":"2023","unstructured":"Li C, Guan N and Liu F. T7 peptide-decorated exosome-based nanocarrier system for delivery of galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma. J Neurooncol 2023; 162: 93-108.","journal-title":"J Neurooncol"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Messaoudi K, Clavreul A, Danhier F, Saulnier P, Benoit J, Lagarce F. Combined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomide. Eur J Nanomed 2015; 7.","DOI":"10.1515\/ejnm-2014-0041"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.drudis.2015.02.014","article-title":"Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide","volume":"20","author":"Messaoudi","year":"2015","unstructured":"Messaoudi K, Clavreul A and Lagarce F. Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide. Drug Discov Today 2015; 20: 772-779.","journal-title":"Drug Discov Today"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/neuonc\/noac071","article-title":"Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy","volume":"24","author":"Zhan","year":"2022","unstructured":"Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q, Fang C, Tan Y, Li L, Xu C, Yuan X and Kang C. Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro Oncol 2022; 24: 1871-1883.","journal-title":"Neuro Oncol"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Zhang C, Song J, Lou L, Qi X, Zhao L, Fan B, Sun G, Lv Z, Fan Z, Jiao B and Yang J. Doxorubicin-loaded nanoparticle coated with endothelial cells-derived exosomes for immunogenic chemotherapy of glioblastoma. Bioeng Transl Med 2020; 6: e10203.","DOI":"10.1002\/btm2.10203"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Zou Y, Sun X, Yang Q, Zheng M, Shimoni O, Ruan W, Wang Y, Zhang D, Yin J, Huang X, Tao W, Park JB, Liang XJ, Leong KW and Shi B. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv 2022; 8: eabm8011.","DOI":"10.1126\/sciadv.abm8011"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1021\/acsbiomaterials.3c00263","article-title":"Angiopep-2 grafted PAMAM dendrimers for the targeted delivery of temozolomide: in vitro and in vivo effects of PEGylation in the management of glioblastoma multiforme","volume":"9","author":"Sahoo","year":"2023","unstructured":"Sahoo RK, Kumar H, Jain V, Sinha S, Ajazuddin and Gupta U. Angiopep-2 grafted PAMAM dendrimers for the targeted delivery of temozolomide: in vitro and in vivo effects of PEGylation in the management of glioblastoma multiforme. ACS Biomater Sci Eng 2023; 9: 4288-4301.","journal-title":"ACS Biomater Sci Eng"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.7150\/thno.22482","article-title":"Targeted delivery of functionalized upconversion nanoparticles for externally triggered photothermal\/photodynamic therapies of brain glioblastoma","volume":"8","author":"Tsai","year":"2018","unstructured":"Tsai YC, Vijayaraghavan P, Chiang WH, Chen HH, Liu TI, Shen MY, Omoto A, Kamimura M, Soga K and Chiu HC. Targeted delivery of functionalized upconversion nanoparticles for externally triggered photothermal\/photodynamic therapies of brain glioblastoma. Theranostics 2018; 8: 1435-1448.","journal-title":"Theranostics"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1039\/D2NR00436D","article-title":"Rational design of ROS-responsive nanocarriers for targeted X-ray-induced photodynamic therapy and cascaded chemotherapy of intracranial glioblastoma","volume":"14","author":"Zhang","year":"2022","unstructured":"Zhang B, Xue R and Sun C. Rational design of ROS-responsive nanocarriers for targeted X-ray-induced photodynamic therapy and cascaded chemotherapy of intracranial glioblastoma. Nanoscale 2022; 14: 5054-5067.","journal-title":"Nanoscale"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","article-title":"Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications","volume":"138","author":"Dadfar","year":"2019","unstructured":"Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Knuchel R, Kiessling F and Lammers T. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 2019; 138: 302-325.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"114822","DOI":"10.1016\/j.addr.2023.114822","article-title":"Magnetic iron oxide nanoparticles for brain imaging and drug delivery","volume":"197","author":"Qiao","year":"2023","unstructured":"Qiao R, Fu C, Forgham H, Javed I, Huang X, Zhu J, Whittaker AK and Davis TP. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv Drug Deliv Rev 2023; 197: 114822.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jconrel.2022.03.007","article-title":"Blood-brain barrier crossing using magnetic stimulated nanoparticles","volume":"345","author":"Chen","year":"2022","unstructured":"Chen J, Yuan M, Madison CA, Eitan S and Wang Y. Blood-brain barrier crossing using magnetic stimulated nanoparticles. J Control Release 2022; 345: 557-571.","journal-title":"J Control Release"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"15594","DOI":"10.1038\/ncomms15594","article-title":"Magnetic forces enable controlled drug delivery by disrupting endothelial cell-cell junctions","volume":"8","author":"Qiu","year":"2017","unstructured":"Qiu Y, Tong S, Zhang L, Sakurai Y, Myers DR, Hong L, Lam WA and Bao G. Magnetic forces enable controlled drug delivery by disrupting endothelial cell-cell junctions. Nat Commun 2017; 8: 15594.","journal-title":"Nat Commun"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"11336","DOI":"10.1021\/acsami.6b02838","article-title":"Superparamagnetic iron oxide nanoparticles modified with tween 80 pass through the intact blood-brain barrier in rats under magnetic field","volume":"8","author":"Huang","year":"2016","unstructured":"Huang Y, Zhang B, Xie S, Yang B, Xu Q and Tan J. Superparamagnetic iron oxide nanoparticles modified with tween 80 pass through the intact blood-brain barrier in rats under magnetic field. ACS Appl Mater Interfaces 2016; 8: 11336-11341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/biom13030573","article-title":"Grafting of cyclodextrin to theranostic nanoparticles improves blood-brain barrier model crossing","volume":"13","author":"Puglisi","year":"2023","unstructured":"Puglisi A, Bognanni N, Vecchio G, Bayir E, van Oostrum P, Shepherd D, Platt F and Reimhult E. Grafting of cyclodextrin to theranostic nanoparticles improves blood-brain barrier model crossing. Biomolecules 2023; 13: 573.","journal-title":"Biomolecules"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.actbio.2019.01.064","article-title":"Brain and bone cancer targeting by a ferrofluid composed of superparamagnetic iron-oxide\/silica\/carbon nanoparticles (earthicles)","volume":"88","author":"VM","year":"2019","unstructured":"Wu VM, Huynh E, Tang S and Uskokovic V. Brain and bone cancer targeting by a ferrofluid composed of superparamagnetic iron-oxide\/silica\/carbon nanoparticles (earthicles). Acta Biomater 2019; 88: 422-447.","journal-title":"Acta Biomater"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"819516","DOI":"10.3389\/fphar.2022.819516","article-title":"Extracellular vesicle-mediated delivery of ultrasmall superparamagnetic iron oxide nanoparticles to mice brain","volume":"13","author":"Kutchy","year":"2022","unstructured":"Kutchy NA, Ma R, Liu Y, Buch S and Hu G. Extracellular vesicle-mediated delivery of ultrasmall superparamagnetic iron oxide nanoparticles to mice brain. Front Pharmacol 2022; 13: 819516.","journal-title":"Front Pharmacol"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1039\/C5TB02123E","article-title":"Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy","volume":"4","author":"Mu","year":"2016","unstructured":"Mu Q, Lin G, Patton VK, Wang K, Press OW and Zhang M. Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy. J Mater Chem B 2016; 4: 32-36.","journal-title":"J Mater Chem B"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3390\/nano10030477","article-title":"Salinomycin-loaded iron oxide nanoparticles for glioblastoma therapy","volume":"10","author":"Norouzi","year":"2020","unstructured":"Norouzi M, Yathindranath V, Thliveris JA and Miller DW. Salinomycin-loaded iron oxide nanoparticles for glioblastoma therapy. Nanomaterials (Basel) 2020; 10: 477.","journal-title":"Nanomaterials (Basel)"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"119342","DOI":"10.1016\/j.biomaterials.2019.119342","article-title":"Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide","volume":"218","author":"Sukumar","year":"2019","unstructured":"Sukumar UK, Bose RJC, Malhotra M, Babikir HA, Afjei R, Robinson E, Zeng Y, Chang E, Habte F, Sinclair R, Gambhir SS, Massoud TF and Paulmurugan R. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials 2019; 218: 119342.","journal-title":"Biomaterials"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"1248283","DOI":"10.3389\/fbioe.2023.1248283","article-title":"Chlorin e6-modified iron oxide nanoparticles for photothermal-photodynamic ablation of glioblastoma cells","volume":"11","author":"Yao","year":"2023","unstructured":"Yao H and Zhou JY. Chlorin e6-modified iron oxide nanoparticles for photothermal-photodynamic ablation of glioblastoma cells. Front Bioeng Biotechnol 2023; 11: 1248283.","journal-title":"Front Bioeng Biotechnol"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C and Stegh AH. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med 2021; 13: eabb3945.","DOI":"10.1126\/scitranslmed.abb3945"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Young JS, Bernal G, Polster SP, Nunez L, Larsen GF, Mansour N, Podell M and Yamini B. Convection-enhanced delivery of polymeric nanoparticles encapsulating chemotherapy in canines with spontaneous supratentorial tumors. World Neurosurg 2018; 117: e698-e704.","DOI":"10.1016\/j.wneu.2018.06.114"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"1104625","DOI":"10.3389\/fimmu.2022.1104625","article-title":"Inhibition of galectins in cancer: biological challenges for their clinical application","volume":"13","author":"Laderach","year":"2023","unstructured":"Laderach DJ and Compagno D. Inhibition of galectins in cancer: biological challenges for their clinical application. Front Immunol 2023; 13: 1104625.","journal-title":"Front Immunol"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1038\/s41467-019-11441-0","article-title":"Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease","volume":"10","author":"Siew","year":"2019","unstructured":"Siew JJ, Chen HM, Chen HY, Chen HL, Chen CM, Soong BW, Wu YR, Chang CP, Chan YC, Lin CH, Liu FT and Chern Y. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat Commun 2019; 10: 3473.","journal-title":"Nat Commun"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/brb3.75","article-title":"Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis","volume":"2","author":"Lerman","year":"2012","unstructured":"Lerman BJ, Hoffman EP, Sutherland ML, Bouri K, Hsu DK, Liu FT, Rothstein JD and Knoblach SM. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav 2012; 2: 563-575.","journal-title":"Brain Behav"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"8116","DOI":"10.3390\/ijms24098116","article-title":"Development of galectin-3 targeting drugs for therapeutic applications in various diseases","volume":"24","author":"Ahmed","year":"2023","unstructured":"Ahmed R, Anam K and Ahmed H. Development of galectin-3 targeting drugs for therapeutic applications in various diseases. Int J Mol Sci 2023; 24: 8116.","journal-title":"Int J Mol Sci"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1039\/C9MD00183B","article-title":"Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors","volume":"10","author":"Dahlqvist","year":"2019","unstructured":"Dahlqvist A, Zetterberg FR, Leffler H and Nilsson UJ. Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors. Medchemcomm 2019; 10: 913-925.","journal-title":"Medchemcomm"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cmdc.202000742","article-title":"Targeting the CRD F-face of human galectin-3 and allosterically modulating glycan binding by angiostatic PTX008 and a structurally optimized derivative","volume":"16","author":"Miller","year":"2021","unstructured":"Miller MC, Zheng Y, Suylen D, Ippel H, Canada FJ, Berbis MA, Jimenez-Barbero J, Tai G, Gabius HJ and Mayo KH. Targeting the CRD F-face of human galectin-3 and allosterically modulating glycan binding by angiostatic PTX008 and a structurally optimized derivative. ChemMedChem 2021; 16: 713-723.","journal-title":"ChemMedChem"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"16980","DOI":"10.1021\/acs.jmedchem.3c01787","article-title":"Discovery of selective and orally available galectin-1 inhibitors","volume":"66","author":"Zetterberg","year":"2023","unstructured":"Zetterberg FR, Diehl C, Hakansson M, Kahl-Knutson B, Leffler H, Nilsson UJ, Peterson K, Roper JA and Slack RJ. Discovery of selective and orally available galectin-1 inhibitors. J Med Chem 2023; 66: 16980-16990.","journal-title":"J Med Chem"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tibtech.2018.10.001","article-title":"Galectin-carbohydrate interactions in biomedicine and biotechnology","volume":"37","author":"Laaf","year":"2019","unstructured":"Laaf D, Bojarova P, Elling L and Kren V. Galectin-carbohydrate interactions in biomedicine and biotechnology. Trends Biotechnol 2019; 37: 402-415.","journal-title":"Trends Biotechnol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"121163","DOI":"10.1016\/j.biomaterials.2021.121163","article-title":"Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma","volume":"278","author":"Zhang","year":"2021","unstructured":"Zhang Y, Xi K, Fu X, Sun H, Wang H, Yu D, Li Z, Ma Y, Liu X, Huang B, Wang J, Li G, Cui J, Li X and Ni S. Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma. Biomaterials 2021; 278: 121163.","journal-title":"Biomaterials"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12951-020-00684-5","article-title":"Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme","volume":"18","author":"Choi","year":"2020","unstructured":"Choi J, Kim G, Cho SB and Im HJ. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme. J Nanobiotechnology 2020; 18: 122.","journal-title":"J Nanobiotechnology"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/2\/ajcr0154415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:43Z","timestamp":1766022763000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/2\/ajcr0154415.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":160,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/mkiv1986","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}